SCHEMBL1905359

SCHEMBL1905359

Cc1noc(C)c1-c1ccc2c(O)ccnc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 12/20 0.56
ERN1 O75460 1/20 0.53
CREBBP Q92793 1/20 0.50
LMNA P02545 4/20 0.49
CYP1A2 P05177 3/20 0.49
HIF1A Q16665 3/20 0.49
CYP2C19 P33261 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
TSHR P16473 1/20 0.49
CYP3A4 P08684 3/20 0.48
CYP2C9 P11712 1/20 0.48
SLC2A1 P11166 1/20 0.48
BRD2 P25440 4/20 0.47
BRD3 Q15059 3/20 0.47
JAK2 O60674 1/20 0.46
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11980656 0.79 BRD4 (0.51) BRD4ERN1CREBBPLMNACYP1A2
SCHEMBL18249987 0.77 NSD3 (0.50) BRD4ERN1LMNACYP1A2CYP2C19
SCHEMBL18249960 0.77 BRD4 (0.49) BRD4ERN1CREBBPLMNACYP1A2
SCHEMBL1904100 0.76 BRD4 (0.63) BRD4ERN1CREBBPLMNACYP1A2
SCHEMBL11985075 0.75 BRD4 (0.61) BRD4CREBBPCYP2C19CYP3A4CYP2C9
SCHEMBL18249909 0.75 BRD4 (0.47) BRD4ERN1CREBBPLMNACYP1A2
SCHEMBL1902354 0.74 ERN1 (0.53) BRD4ERN1CREBBPLMNACYP1A2
SCHEMBL22120038 0.73 LMNA (0.54) BRD4ERN1CREBBPLMNACYP1A2
SCHEMBL21253776 0.72 BRD4 (0.71) BRD4CREBBPLMNACYP1A2HIF1A
SCHEMBL18895175 0.72 ERN1 (0.51) BRD4ERN1CREBBPLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150133436-A1 Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases GLAXOSMITHKLINE LLC 2015-05-14 US disclosed
WO-2015049629-A1 IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS Piramal Enterprises Limited (IN) 2015-04-09 WO disclosed
EP-2496576-B1 IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-12-18 EP disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
EP-2496576-A1 IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
EP-2496235-A1 BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
US-20120208800-A1 Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases GLAXOSMITHKLINE LLC 2012-08-16 US disclosed
WO-2011054843-A1 BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208800-A1 Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases BRD4, BRD3, BRPF3 BRD4 1/4885ERN1 1377/4885CREBBP 29/4885
US-20150133436-A1 Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases BRD4, BRD3, BRPF3 BRD4 1/4885ERN1 1377/4885CREBBP 29/4885
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors BRD4, BRD3, BRPF3 BRD4 1/4885ERN1 2441/4885CREBBP 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.